Considering that MS would be simple to implement for new hotspot mutations, we extended our MS assay to evaluate mutations in the TERT promoter, which are not yet required by WHO, but are characteristic of both ODGs and GBMs and have recently been determined to have specific prognostic value in the molecular classification of gliomas [8, 22, 26]; moreover, TERT is also a potential therapeutic target, as recently demonstrated by the results obtained by Imetelstat treatment on various type of hematological and solid tumors [18, 19, 38, 39]. The gene discussed is TERT; the disease is central nervous system cancer.